1. Secondary Cytoreduction Versus Chemotherapy Alone in the Treatment of Patients with Recurrent Ovarian Cancer: Is a Randomized Trial Worthwhile?

   • Paolo Sammartino
   • Daniele Biacchi
   • Marialuisa Framarino

   Letter to the Editor 28 February 2013 Pages: 191 - 191

2. In Reply: Response to Sammartino et al.

   • Philipp Harter
   • Florian Heitz
   • Andreas du Bois

   Letter to the Editor 28 February 2013 Pages: 192 - 192

3. Provider Impact on Survival Outcomes in the Management of Malignant Disease

   • Maurie Markman

   Invited Commentary 22 February 2013 Pages: 193 - 196

4. Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed?

   • Keiichi Fujiwara
   • Akira Kurosaki
   • Kosei Hasegawa

   Invited Commentary 16 March 2013 Pages: 197 - 200

   

5. Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice?

   • Susana Banerjee
   • Martin Gore

   Invited Commentary 27 March 2013 Pages: 201 - 203

6. Follow-Up of Epithelial Ovarian Cancer: Overdue For A Major Rethink

   • Paul Hoskins

   Invited Commentary 13 March 2013 Pages: 204 - 206

7. The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion

   • Michael Bradshaw
   • Aaron Mansfield
   • Tobias Peikert

   Hot Topic 10 April 2013 Pages: 207 - 216

8. Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer

   • Sausan Abouharb
   • Paul G. Corn

   Genitourinary Cancers (E Jonasch, Section Editor) 09 April 2013 Pages: 217 - 223

9. Novel Immunotherapies in GU Malignancies

   • Alexandra Drakaki
   • David F. McDermott

   Genitourinary Cancers (E Jonasch, Section Editor) 22 March 2013 Pages: 224 - 231

10. Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference?

    • Yago Nieto

    Genitourinary Cancers (E Jonasch, Section Editor) 14 March 2013 Pages: 232 - 238

11. New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer

    • Erin E. Ezzell
    • Kuang S. Chang
    • Benjamin J. George

    Genitourinary Cancers (E Jonasch, Section Editor) 27 February 2013 Pages: 239 - 248

    

12. Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem

    • Viswanath Reddy Belum
    • Alyssa Fischer
    • Mario E. Lacouture

    Palliative Medicine (A Jatoi, Section Editor) 06 March 2013 Pages: 249 - 259

    

13. Clearing the Air: A Review of Our Current Understanding of “Chemo Fog”

    • Erin O’Farrell
    • Joyce MacKenzie
    • Barbara Collins

    Palliative Medicine (A Jatoi, Section Editor) 13 March 2013 Pages: 260 - 269

14. Benefit and Harms of New Anti-Cancer Drugs

    • Francisco E. Vera-Badillo
    • Mustafa Al-Mubarak
    • Eitan Amir

    Palliative Medicine (A Jatoi, Section Editor) 23 February 2013 Pages: 270 - 275

    

15. Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?

    • Morgan Trammel
    • Mary Roederer
    • Howard McLeod

    Palliative Medicine (A Jatoi, Section Editor) 21 March 2013 Pages: 276 - 285